Observations suggest that bovine-derived colostrum preparations deliver biologically active concentrations of speciﬁc antibodies to the intestinal lumen when taken orally, and might be capable of blocking various forms of bacterial toxins in the gut by that mechanism.
Since microbial translocation is driving immune activation and progression of liver disease, strategies that reduce or prevent microbial translocation may have a signiﬁcant impact on immune activation, and thus on the natural history of chronic Hepatitis C Virus infection. The present invention now demonstrates the use of bovine colostrum powder (BPC) preparations from immunized cows, containing high levels of antibodies, as immunomodulators capable of reducing immune activation in response to microbial products such as LPS.
Without being bound to any theory, the inventors hypothesize that the attachment of the BPC antibodies to the microbial antigens may prevent their translocation onto the blood stream, thereby restricting the immune response. These effects upon the immune system enable the use of such colostrum preparations for the treatment of infectious disease, which involve the immune system. More speciﬁcally, the present invention provides the use of a colostrum-derived preparation, comprising high concentrations of anti-LPS antibodies, in the treatment and amelioration of chronic liver diseases.
Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a microbiome company focused on developing and commercialising oral immunotherapeutics for the treatment of many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The Company currently markets and sells Travelan® for the prevention of travellers’ diarrhoea and has two lead clinical assets. IMM-124E is in Phase 2 clinical trials for NASH, ASH and pediatric NAFLD and IMM-529 is in clinical development for clostridium diﬃcile infections. These products together with the Company’s other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large unmet need in the market.
Antibodies against endotoxins are also contained in the natural spectrum of antibodies from bovine colostrum.
did you know?
E. coli is commonly isolated in patients with bacterial overgrowth. Certain species of bacteria are more commonly found in aspirates of the jejunum taken from patients with bacterial overgrowth.
The most common isolates are:
- • Escherichia coli
- • Streptococcus
- • Lactobacillus
- • Bacteroides
- • Enterococcusspecies
Many patients with chronic diarrhea have bacterial overgrowth as a cause or a contributor to their symptoms. Various mechanisms are involved in the development of diarrhea in bacterial overgrowth. First, the excessive bacterial concentrations can cause direct inﬂammation of the small bowel cells, leading to an inﬂammatory diarrhea. The malabsorption of lipids, proteins and carbohydrates may cause poorly digestible products to enter into the colon. This can cause diarrhea by the osmotic drive of these molecules, but can also stimulate the secretory mechanisms of colonic cells, leading to a secretory diarrhea. SIBO can sometimes be triggered by an acute gastrointestinal infection.
Colostrum Goes Biotech
3 A novel extract from bovine colostrum whey supports anti-bacterial and anti-viral innate immune functions in vitro and in vivo: I. Enhanced immune activity in vitro translates to improved microbial clearance in animal infection models.
^scroll down patent page to see this and all patents by Immuron® Ltd., link won’t go directly to page.